BRCA in breast cancer: From risk assessment to therapeutic prediction

Jennifer R. Diamond, Virginia F. Borges, S Gail Eckhardt, Antonio Jimeno

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

BRCA1/2 mutations are the most commonly identified germ line gene mutations in patients with hereditary breast cancer. These proteins have many critical cellular functions, including repair of DNA double-strand breaks. The role of defective BRCA1/2 as a predictor of response to DNA-damaging agents has been studied extensively in preclinical models, but prospective clinical validation is lacking. Poly [ADP-ribose] polymerase (PARP) inhibitors illustrate the concept of synthetic lethality in cells with defective BRCA1/2 and numerous PARP inhibitors are being evaluated in patients with BRG47/2-associated tumors. BRCA1/2 mutation or functional loss will likely serve as a useful predictive biomarker of response to treatment with PARP inhibitors.

Original languageEnglish (US)
Pages (from-to)603-608
Number of pages6
JournalDrug News and Perspectives
Volume22
Issue number10
DOIs
StatePublished - Dec 1 2009

Fingerprint

Breast Neoplasms
Mutation
Double-Stranded DNA Breaks
Germ-Line Mutation
Therapeutics
Biomarkers
DNA
Genes
Poly(ADP-ribose) Polymerase Inhibitors
Neoplasms
Proteins
Synthetic Lethal Mutations

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Cite this

BRCA in breast cancer : From risk assessment to therapeutic prediction. / Diamond, Jennifer R.; Borges, Virginia F.; Eckhardt, S Gail; Jimeno, Antonio.

In: Drug News and Perspectives, Vol. 22, No. 10, 01.12.2009, p. 603-608.

Research output: Contribution to journalReview article

Diamond, Jennifer R. ; Borges, Virginia F. ; Eckhardt, S Gail ; Jimeno, Antonio. / BRCA in breast cancer : From risk assessment to therapeutic prediction. In: Drug News and Perspectives. 2009 ; Vol. 22, No. 10. pp. 603-608.
@article{9e729bfe3943427f89de5f470c38eaa1,
title = "BRCA in breast cancer: From risk assessment to therapeutic prediction",
abstract = "BRCA1/2 mutations are the most commonly identified germ line gene mutations in patients with hereditary breast cancer. These proteins have many critical cellular functions, including repair of DNA double-strand breaks. The role of defective BRCA1/2 as a predictor of response to DNA-damaging agents has been studied extensively in preclinical models, but prospective clinical validation is lacking. Poly [ADP-ribose] polymerase (PARP) inhibitors illustrate the concept of synthetic lethality in cells with defective BRCA1/2 and numerous PARP inhibitors are being evaluated in patients with BRG47/2-associated tumors. BRCA1/2 mutation or functional loss will likely serve as a useful predictive biomarker of response to treatment with PARP inhibitors.",
author = "Diamond, {Jennifer R.} and Borges, {Virginia F.} and Eckhardt, {S Gail} and Antonio Jimeno",
year = "2009",
month = "12",
day = "1",
doi = "10.1358/dnp.2009.22.10.1443393",
language = "English (US)",
volume = "22",
pages = "603--608",
journal = "Drug News and Perspectives",
issn = "0214-0934",
publisher = "Prous Science",
number = "10",

}

TY - JOUR

T1 - BRCA in breast cancer

T2 - From risk assessment to therapeutic prediction

AU - Diamond, Jennifer R.

AU - Borges, Virginia F.

AU - Eckhardt, S Gail

AU - Jimeno, Antonio

PY - 2009/12/1

Y1 - 2009/12/1

N2 - BRCA1/2 mutations are the most commonly identified germ line gene mutations in patients with hereditary breast cancer. These proteins have many critical cellular functions, including repair of DNA double-strand breaks. The role of defective BRCA1/2 as a predictor of response to DNA-damaging agents has been studied extensively in preclinical models, but prospective clinical validation is lacking. Poly [ADP-ribose] polymerase (PARP) inhibitors illustrate the concept of synthetic lethality in cells with defective BRCA1/2 and numerous PARP inhibitors are being evaluated in patients with BRG47/2-associated tumors. BRCA1/2 mutation or functional loss will likely serve as a useful predictive biomarker of response to treatment with PARP inhibitors.

AB - BRCA1/2 mutations are the most commonly identified germ line gene mutations in patients with hereditary breast cancer. These proteins have many critical cellular functions, including repair of DNA double-strand breaks. The role of defective BRCA1/2 as a predictor of response to DNA-damaging agents has been studied extensively in preclinical models, but prospective clinical validation is lacking. Poly [ADP-ribose] polymerase (PARP) inhibitors illustrate the concept of synthetic lethality in cells with defective BRCA1/2 and numerous PARP inhibitors are being evaluated in patients with BRG47/2-associated tumors. BRCA1/2 mutation or functional loss will likely serve as a useful predictive biomarker of response to treatment with PARP inhibitors.

UR - http://www.scopus.com/inward/record.url?scp=77949514782&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77949514782&partnerID=8YFLogxK

U2 - 10.1358/dnp.2009.22.10.1443393

DO - 10.1358/dnp.2009.22.10.1443393

M3 - Review article

C2 - 20140280

AN - SCOPUS:77949514782

VL - 22

SP - 603

EP - 608

JO - Drug News and Perspectives

JF - Drug News and Perspectives

SN - 0214-0934

IS - 10

ER -